Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Orchestra BioMed Inc.

    NASDAQ: OBIO · Real-Time Price · USD
    2.81
    -0.17 (-5.70%)
    At close: Jun 27, 2025, 3:59 PM
    2.78
    -0.87%
    After-hours: Jun 27, 2025, 04:16 PM EDT

    Orchestra BioMed Statistics

    Share Statistics

    Orchestra BioMed has 38.31M shares outstanding. The number of shares has increased by 6.22% in one year.

    Shares Outstanding

    n/a
    		 38.31M

    Shares Change (YoY)

    n/a
    		 6.22%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 49.81%

    Shares Floating

    n/a
    		 26.75M

    Failed to Deliver (FTD) Shares

    n/a
    		 13,798

    FTD / Avg. Volume

    n/a
    		 3.18%

    Short Selling Information

    The latest short interest is 1.21M, so 3.16% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.21M

    Short % of Shares Out

    n/a
    		 3.16%

    Short % of Float

    n/a
    		 6.48%

    Short Ratio (days to cover)

    n/a
    		 9.12

    Valuation Ratios

    The PE ratio is -2.41 and the forward PE ratio is -1.75. Orchestra BioMed's PEG ratio is -0.2.

    PE Ratio

    n/a
    		 -2.41

    Forward PE

    n/a
    		 -1.75

    PS Ratio

    n/a
    		 55.83

    Forward PS

    n/a
    		 2

    PB Ratio

    n/a
    		 4.47

    P/FCF Ratio

    n/a
    		 -2.9

    PEG Ratio

    n/a
    		 -0.2
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Orchestra BioMed.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.27, with a Debt / Equity ratio of 0.5.

    Current Ratio

    n/a
    		 4.27

    Quick Ratio

    n/a
    		 4.26

    Debt / Equity

    n/a
    		 0.5

    Debt / EBITDA

    n/a
    		 -0.26

    Debt / FCF

    n/a
    		 -0.33

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $37,685.71

    Profits Per Employee

    n/a
    		 $-871,771.43

    Employee Count

    n/a
    		 70

    Asset Turnover

    n/a
    		 0.03

    Inventory Turnover

    n/a
    		 1.18

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -62.17% in the last 52 weeks. The beta is 0.63, so Orchestra BioMed's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.63

    52-Week Price Change

    n/a
    		 -62.17%

    50-Day Moving Average

    n/a
    		 2.92

    200-Day Moving Average

    n/a
    		 4.5

    Relative Strength Index (RSI)

    n/a
    		 46.72

    Average Volume (20 Days)

    n/a
    		 433,596

    Income Statement

    In the last 12 months, Orchestra BioMed had revenue of 2.64M and earned -61.02M in profits. Earnings per share was -1.66.

    Revenue

    n/a
    		 2.64M

    Gross Profit

    n/a
    		 2.43M

    Operating Income

    n/a
    		 -64.3M

    Net Income

    n/a
    		 -61.02M

    EBITDA

    n/a
    		 -64.3M

    EBIT

    n/a
    		 -64.3M

    Earnings Per Share (EPS)

    n/a
    		 -1.66
    Full Income Statement

    Balance Sheet

    The company has 22.26M in cash and 16.53M in debt, giving a net cash position of 5.73M.

    Cash & Cash Equivalents

    n/a
    		 22.26M

    Total Debt

    n/a
    		 16.53M

    Net Cash

    n/a
    		 5.73M

    Retained Earnings

    n/a
    		 -309.88M

    Total Assets

    n/a
    		 59.05M

    Working Capital

    n/a
    		 36.41M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -50.56M and capital expenditures -289K, giving a free cash flow of -50.85M.

    Operating Cash Flow

    n/a
    		 -50.56M

    Capital Expenditures

    n/a
    		 -289K

    Free Cash Flow

    n/a
    		 -50.85M

    FCF Per Share

    n/a
    		 -1.38
    Full Cash Flow Statement

    Margins

    Gross margin is 92.27%, with operating and profit margins of -2437.49% and -2313.27%.

    Gross Margin

    n/a
    		 92.27%

    Operating Margin

    n/a
    		 -2437.49%

    Pretax Margin

    n/a
    		 -2313.27%

    Profit Margin

    n/a
    		 -2313.27%

    EBITDA Margin

    n/a
    		 -2437.49%

    EBIT Margin

    n/a
    		 -2437.49%

    FCF Margin

    n/a
    		 -1927.48%

    Dividends & Yields

    OBIO does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for OBIO is $12, which is 300% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $12

    Price Target Difference

    n/a
    		 300%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -9.31

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist